a public good project by the
Synthesis
Company
of California

© 2026

Satoshi Motoya | doi.page

0 works0 citations0 h-index

Satoshi Motoya

Japan Pediatric Society(JP)Sapporo Kosei General Hospital(JP)

Publications by Year

Research Areas

Inflammatory Bowel Disease, Microscopic Colitis, Immunodeficiency and Autoimmune Disorders, Autoimmune and Inflammatory Disorders, Helicobacter pylori-related gastroenterology studies

Most-Cited Works

→ Evidence-based clinical practice guidelines for inflammatory bowel disease(2018)687 cited
→ Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial(2016)234 cited
→ Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease(2020)229 cited
→ Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis(2013)163 cited
→ A Genome-Wide Association Study Identifies 2 Susceptibility Loci for Crohn's Disease in a Japanese Population(2012)138 cited
→ Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis(2015)136 cited

→ An Open-Label Prospective Randomized Multicenter Study Shows Very Rapid Remission of Ulcerative Colitis by Intensive Granulocyte and Monocyte Adsorptive Apheresis as Compared With Routine Weekly Treatment(2009)

128 cited

→ NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study(2018)123 cited

→ First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis(2015)115 cited

→ Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease(2014)101 cited